Abstract:Background: Lipoprotein(a) (Lp[a]) is a circulating plasma lipoprotein that is emerging as an important independent risk factor for vascular disease. Lp(a) levels are 75-90% heritable, predominantly determined by copy number variation and single nucleotide polymorphisms (SNPs) at the LPA gene. Methods: Using ~370K individuals with serum measurements of Lp(a) in the UK Biobank European cohort, we constructed a genetic risk score (GRS) consisting of 29 SNPs in the vicinity of LPA which explained 68.18% of variation in Lp(a). Using the LPA GRS to instrument Lp(a), we conducted phenome-wide Mendelian randomization analysis (MR-PheWAS) across a spectrum of 489 medically-relevant phenotypes in ~7.3M individuals from the 23andMe, Inc. database, and compared effects to those derived from a GRS for low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB). Through multivariable MR, we sought to assess the direct causal effect of Lp(a) on cardiovascular disease risks while keeping LDL-C or apoB constant. Results: MR-PheWAS confirmed previously reported Lp(a) causal effects on coronary artery disease (CAD: OR = 1.199, 95% CI = [1.193, 1.205], p-value < 2.23e-308, for every 59.632 nmol/L higher Lp(a) instrumented by the LPA GRS), and revealed additional genetically-predicted effects largely confined to cardiovascular endpoints, including a novel effect for restrictive cardiomyopathy (OR = 1.101, 95% CI = [1.068, 1.134], p-value = 3e-10). We scaled the LPA, LDL-C and apoB GRS such that they each had the same OR for MACE (major adverse cardiovascular events). Using the scaling rubric, similar magnitudes of effect were seen for the three lipid traits for most vascular diseases, with the exception of peripheral artery disease, aortic stenosis and dilated cardiomyopathy, where Lp(a) had larger genetically-predicted effect sizes compared to LDL-C and apoB. Multivariable MR identified Lp(a) to retain a causal effect on MACE while accounting for LDL-C or apoB. To achieve the 25% relative risk reduction in major vascular events, as seen with a 1 mmol/L reduction in LDL-C from statin trials, we anticipate that Lp(a) ought to be reduced by ~ 90 mg/dL (200 nmol/L), highlighting the importance of not only using therapies that have a profound impact on Lp(a) lowering, but also selecting individuals that have high Lp(a) concentrations at baseline. Conclusion: Lp(a) has genetically-predicted causal effects on a broad range of cardiovascular diseases beyond CAD, with minimal effects seen for non-vascular disease.

Weighted burden analysis of rare coding variants in 470,000 exome-sequenced UK Biobank participants characterises effects on hyperlipidaemia risk

Investigation of recessive effects of coding variants on common clinical phenotypes in exome-sequenced UK Biobank participants

Exome wide association study for blood lipids in 1,158,017 individuals from diverse populations

Whole-exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol.

Coding-Sequence Variants Are Associated with Blood Lipid Levels in 14,473 Chinese

Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese

Analysis of 470,000 exome-sequenced UK Biobank participants identifies genes containing rare variants which confer dementia risk

Combining evidence from human genetic and functional screens to identify pathways altering obesity and fat distribution

Whole Genome Sequence Analysis of Blood Lipid Levels in >66,000 Individuals

Novel Common Variants Associated with Body Mass Index and Coronary Artery Disease Detected Using a Pleiotropic Cfdr Method.

Exome Chip Meta-Analysis Identifies Novel Loci and East Asian–specific Coding Variants That Contribute to Lipid Levels and Coronary Artery Disease

Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed Whole Genome Sequencing Study

Identification of Rare Loss-of-Function Genetic Variation Regulating Body Fat Distribution

Erratum: A Rare Variant in APOC3 is Associated with Plasma Triglyceride and VLDL Levels in Europeans

Evaluating genetically-predicted causal effects of lipoprotein(a) in human diseases: a phenome-wide Mendelian randomization study

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank

Large-scale functional characterization of low-density lipoprotein receptor gene variants improves risk assessment in cardiovascular disease

Exome sequencing and analysis of 454,787 UK Biobank participants

Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III

Common Variants at 30 Loci Contribute to Polygenic Dyslipidemia